banda transcan 2 2016ul

Title:
Translational Research in Peripheral T-Cell Lymphomas: from characterization to novel targets

Project Coordinator:
Lorenz Truemper (Germany), University Medical Center of Goettingen, Department of Hematology & Oncology, Goettingen

Project Partners:
Reiner Siebert (Germany), Ulm University & Ulm University Medical Center, Dept. of Human Genetics, Ulm
Daphne de Jong (Netherlands), VU University Medical Center, Department of Pathology, Amsterdam
Philipp Staber (Austria), Medical University of Vienna, Department of Medicine I, Division of Hematology & Hemostaseology, Vienna
Olivier Tournilhac (France), Clermont-Ferrand University Hospital, Dept.of Hematology, Clermont-Ferrand

Project Abstract:
Background. Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of rare lymphoid malignancies. With current treatment options, the majority of patients do not achieve remission or experience relapse after completion of therapy, generally with dismal outcome [1-4]. Mechanisms of progression and relapse remain elusive and predictive biomarkers do not exist, precluding clinical progress.
Hypothesis. We hypothesize that utilizing a unique collection of clinically annotated samples from multiple European trials and registries for detailed pathologic assessment and comprehensive characterization of the (epi-) genetic landscape will unravel pivotal mechanisms determining the unique biology and clinical behavior of PTCL.
Aims. Aim 1: Collect a clinically annotated, comprehensively characterized and centrally reviewed sample collection of PTCL. Aim 2: Perform a comprehensive genetic and epigenetic characterization and identify prognostic (epi-) genetic biomarkers. Aim 3: Identify molecular targets and develop novel therapeutic strategies.
Methods. This study will be based on biopsy samples of patients treated in prospective European clinical trials and from population-based cohorts that are collected via the national pathology reference centers. Whole exome sequencing, genome-wide DNA methylation profiling and targeted sequencing results will be correlated with clinical parameters, including progression and outcome. (Epi-) Genetic alterations will be addressed with drug screening assays in pre-clinical models and ex vivo in primary PTCL samples.
Expected results & impact. This study will provide a comprehensively characterized catalogue of clinically annotated samples across the major subtypes of PTCL. The integrated analysis of (epi-) genetic alterations will elucidate pathogenic mechanisms and the correlation with clinical endpoints will provide insight in prognostic biomarkers. Finally, novel therapeutic strategies will be explored on the basis of these data.

 

(Project funded under JTC 2017)


TRANSCAN News

Launch of the call: JTC 2021
The new TRANSCAN-3 project consortium is launching the first Joint Transnational Call for proposals, co-funded by the European Commission, on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment"

International Networking Event (virtual)
on 22 April 2021 hrs 9:00 CET
will focus on the forthcoming co-funded JTC 2021 on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment" 
the event is organized by TUBITAK under the “Turkey in Horizon 2020 Phase II” Technical Assistance Project
in cooperation with TRANSCAN-3

ERA-NET Cofund TRANSCAN-3:
 Sustained collaboration of national and regional programmes in cancer research
is the new project funded by the European Commission under H2020  which started on 1st March 2021 and will last five years (G. A. no. 964264)

A TRANSCAN-2 brochure, highlighting key achievements, is available for download

 

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.

Who's Online

We have 15 guests and no members online